ANBESOL ADULT STRENGTH

Route of administration: oromucosal Adults, the elderly and children over 12 years: apply a small amount to the affected area with a clean fingertip. One application should be sufficient. It should not be used more frequently than every 3 hours.

Undesirable effects are listed by MedDRA System Organ Classes.

Assessment of undesirable effects is based on the following frequency groupings:

Very common: ≥1/10 Common: ≥1/100 to <1/10 Uncommon: ≥1/1,000 to <1/100 Rare: ≥1/10,000 to <1/1,000 Very rare: <1/10,000 Not known: cannot be estimated from the available data System Organ Class Undesirable Effect Frequency Immune system disorders Allergic reactions Not known Gastrointestinal disorders Non-specific ulceration Not known Skin and subcutaneous tissue disorders Dermatitis Not known Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store.

Not suitable for treatment of teething in children. 9). Anbesol should be used with caution in patients with wounds or traumatised mucosa in the region of the proposed application. A damaged mucosa will permit increased systemic absorption resulting in systemic effects, such as convulsions, particularly if excessive quantities are used.

This medicinal product contains chlorocresol which may cause allergic reactions in sensitive individuals. 9% w/w ethanol 100%). The small amount of alcohol in this medicine will not have any noticeable effects.

1. Lidocaine is considered to be unsafe in patients with porphyria because it has been shown to be porphyrinogenic in animals.